Study | PCD | Healthy controls | Cystic fibrosis | |||

Stationary | Portable | Stationary | Portable | Stationary | Portable | |

Montella et al. [38], 2011^{#} | Median 1.5 (range 1.0–2.3), n = 14 | Median 2.6 (range 1.9–3.5), n = 14 | Median 13.7 (range 9.6–19.5), n = 13 | Median 12.4 (range 8.9–17.6), n = 13 | Median 9.5 (range 7.0–13.0), n = 11 | Median 13.4 (range 10.4–17.3), n = 11 |

Harrison et al. [28], 2012^{¶} | Mean±sd 7.2±4.1, n = 4 | Mean±sd 125.7±22.8, n = 5 | Mean±sd 12±11.7, n = 6 | |||

Marthin and Nielsen [17], 2013^{+} | Mean±sd 23.7±22.8, n = 16 | Mean±sd 19.2±18.7, n = 12 | Mean±sd 267±74.4, n = 20 | Mean±sd 180.9±57.7, n = 21 | Mean±sd 150.3±58.8, n = 21 | Mean±sd 97.2±41.6, n = 8 |

Harris et al. [32], 2014^{§} | Median 12.3 (IQR 8.4), n = 11 | Median 5.4 (IQR 3.3), n = 12 | Median 208.2 (IQR 58.8), n = 15 | Median 112.6 (IQR 88.0), n = 15 |

All nasal nitric oxide measurements have units of nL·min

^{−1}. PCD: primary ciliary dyskinesia; IQR: interquartile range.^{#}: nasal exhalation;^{¶}: tidal breathing;^{+}: breath hold;^{§}: tidal breathing (MINO Breathhold – Flex).